CoChat

Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK

Keenan, Tiarnan D L, Kelly, Simon P, Sallam, Ahmed, Mohamed, Quresh, Tufail, Adnan, Johnston, Robert L · 2013 · British Journal of Ophthalmology

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Abstract

AIMS: To analyse the incidence and baseline clinical characteristics of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in a defined UK region. METHODS: A standardised dataset was collected prospectively using an electronic medical record (EMR) system from 1 January 2008 to 21 June 2012 for all patients living in Gloucestershire who received intravitreal anti-VEGF injections for nAMD. RESULTS: Over the study period, 1207 eyes from 1033 patients began intravitreal anti-VEGF injections for nAMD. The annual incidence in the years after National Institute for Health and Care Excellence (NICE) technology appraisal 155 implementation was stable at 120 (95% CI 110 to 138) eyes or 100 (89 to 115) people per 100 000 population. The most common indication was occult choroidal neovascularisation (51%). Median baseline visual acuity (VA) was significantly higher for second treated than first treated eyes (66 and 56 letters, respectively; p<0.0001). Median baseline VA of fellow eyes increased from 47 (2008) to 67 letters (2012; p<0.005). The proportion of patients with baseline VA in the better eye ≥70 letters increased from 27.6% (2008) to 51.4% (2012; p<0.0001), while the proportion eligible at baseline for full or partial certificate of visual impairment decreased from 13.8% (2008) to 7.1% (2012; p<0.05). CONCLUSIONS: The incidence of patients undergoing anti-VEGF therapy for nAMD increased substantially following NICE approval of ranibizumab (August 2008), and has been stable since 2009. This equates to an annual UK incidence of 26 850 (21 320 to 32 440) eyes, similar to NICE estimates. Patients eligible for blindness certification before treatment decreased by half from 2008-2012. Prospective data collection using an EMR system is invaluable for efficient monitoring of real-world clinical care.

Overview

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2013-303233

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 4

  1. The Royal College of Ophthalmologists. AMD Service Provisions Sub- Committee, 2007, Commissioning contemporary AMD services: a guide for commissioners and clinicians (Version 3)
  2. Royal College of Ophthalmologists. AMD Provisions Sub-Committee, 2009, The
  3. National Institute for Health and Clinical Excellence, 2008, Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
  4. Fletcher, 2001, Low vision services for people with age-related macular degeneration in the UK: a review of service need and provision. Macular Disease Society

Cited by

See all 30

Metadata

Authors
Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L.
Affiliations
  • Bolton NHS Foundation Trust (GB)
  • Gloucestershire Hospitals NHS Foundation Trust (GB)
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • Cheltenham General Hospital (GB)
Corresponding author
Johnston, Robert L
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2013-06-28
Volume
97
Issue
9
Pages
1168-1172
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W2152152687
Cited by
29
References
19
Citations by year
2026: 1 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 5 · 2013: 1
FWCI
4.92
Type
journal article
Language
en
Open access
closed
Locations
  • British Journal of Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
neovascular age-related macular degeneration, incidence, anti-VEGF therapy, intravitreal injection, ranibizumab, NICE technology appraisal, baseline visual acuity, Gloucestershire, treatment trends
MeSH terms
Aged, Aged, 80 and over, Female, United Kingdom, Humans, Macular Degeneration, Male, Middle Aged, Prospective Studies, Visual Acuity, Incidence, Age Distribution, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. https://app.cochat.ai/papers/10.1136/bjophthalmol-2013-303233
The paper
Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L. (2013). Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2013-303233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.